¸¶ÀÌÅ©·Î¹ÙÀÌ¿È°ú ¾Ï ¸é¿ª Ä¡·á
Microbiome and Cancer Immunotherapy
´ëÇѳ»°úÇÐȸÁö 2021³â 96±Ç 4È£ p.312 ~ p.317
È«¹®±â(Hong Moon-Ki) - Yonsei University College of Medicine Department of Internal Medicine
Á¤¹Î±Ô(Jung Min-Kyu) - Yonsei University College of Medicine Department of Internal Medicine Division of Medical Oncology
Abstract
Immune checkpoint inhibitors (ICIs) have achieved promising clinical results in cancer treatment over the past decade. However, the efficacy of ICIs is less than 30% in most tumor types, and studies are underway to identify the predictive factors responsive to ICIs. More than 1,000 species of microorganisms live in the human body, and the second human genome project, The Human Microbiome Project, has been conducted to understand human diseases through interactions with microbes. As the microbiome project has progressed, many studies have reported on the association between microorganisms and human diseases, including preclinical and clinical studies on the relationship between ICIs and the microbiome. Therefore, in this manuscript, the relationship between the microbiome and cancer, especially the effectiveness of ICIs, is reviewed.
Å°¿öµå
Gastrointestinal microbiome, Neoplasms, Immune checkpoint inhibitors
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
in this manuscript, the relationship between the microbiome and cancer, especially the effectiveness of Immune checkpoint inhibitors (ICIs), is reviewed.